News Releases

Date Title and Summary View
March 19, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 19, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has...
Additional Formats
March 11, 2021
– Recent KVD900 Phase 2 Clinical Trial Results Statistically and Clinically Significant – – IND Submitted for Oral Prophylactic HAE Treatment Candidate KVD824; Phase 2 Expected to Initiate in Q2 2021 – – Following Upsized Public Offering, Funded to KVD900 NDA Filing – CAMBRIDGE, Mass....
Additional Formats
February 18, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 18, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in...
Additional Formats
February 16, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 16, 2021-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,250 shares of its common stock at a price to the public of $36.00 per share before...
Additional Formats
February 10, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 10, 2021-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share....
Additional Formats
February 9, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 9, 2021-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) announced today that it intends to offer and sell 4,500,000 shares of its common stock in an underwritten public offering. In addition, KalVista intends to grant the underwriters a 30-day option to...
Additional Formats
February 9, 2021
– Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) – – KVD900 Generally Safe and Well-Tolerated – – Conference Call to Discuss Trial Results Today at 8:30 a.m. ET – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb....
Additional Formats
Displaying 21 - 27 of 27